CORMOVE, a subsidiary of PEROUSE MEDICAL, was formed in 2007 and is wholly dedicated to the design of percutaneous cardiac valves. It has lodged many patents for these since 2002.
 
CORMOVE has used all of the expertise from the companies in the PEROUSE MEDICAL group and has invested in leading edge methodological tools, such as FEA (Finite Element Analysis) which model forces applied on the device and predict its behaviour, particularly fatigue behaviour.
 
Product indications and description:
The percutaneous aortic valve is indicated for replacement of a natural aortic valve with severe stenosis (narrowing) using a bioprosthesis introduced endovascularly (along the artery) in patients who have contra-indications to surgery or are at surgical high risk.
 
Currently, more than 30% of patients suffering from aortic stenosis are refused conventional surgery and therefore not operated on.
Since 2002, the development of the percutaneous aortic valves has allowed aortic valve replacement to be considered in a population of patients which was excluded until that point.
 
This also represents an increase in less invasive interventions compared to interventional surgery. It is a new area in which CORMOVE/PEROUSE MEDICAL would like to become established.
 
The CORMOVE percutaneous aortic valve consists of a self-expansible nitinol stent valve and bovine pericardial cusps.
A per-operative stent valve loading device known as a deployment system allows the percutaneous valve to be repositioned if necessary before it is finally positioned in the natural aortic valve. 
This project is co-financed by the European Union and OSEO. Europe is involved in Picardie region with the European regional development fund ERDF.